SAGA Diagnostics to Present Data on Pathlight™ MRD Test at ASCO 2026
SAGA Diagnostics is set to present data on their ultrasensitive Pathlight™ MRD test, which is based on a tumor-informed, structural variant-based ctDNA platform, during the ASCO 2026 conference. The presentation will cover findings related to breast, colon, and rectal cancers, showcasing the test’s application in both metastatic and localized cancer settings.
MORRISVILLE, N.C.–(BUSINESS WIRE)– #ASCO2026–SAGA will present new data supporting Pathlight, its tumor-informed, structural variant-based ctDNA platform, across metastatic and localized cancers.
